Week Ending February 7, 2022

Characterisation of broadly neutralising antibodies against the hepatitis C virus
“The hepatitis C virus (HCV) is a genetically highly variable virus that mutates extensively. An effective vaccine would therefore need to evoke broadly neutralizing antibodies that not only neutralize one HCV strain, but as many of the worldwide circulating genotypes as possible. To date, all attempts to develop a vaccine have failed. A better understanding of the antibody response to HCV is needed in order to provide new impetus to the development of a vaccine. The initial question for the study was therefore: What particular properties of the antibodies against HCV lead to broad neutralization of the virus?”

Hep C treatment van makes cure accessible to those who need it most.
“Yesenia Laguardia has only been a phlebotomist for a few years, but around here she’s known as a vampire. “And that’s a compliment in this community because we’re able to get that blood,” she says as she sits down with Frederick Black outside the Windsor Hotel on Eddy Street.”

Fatty Liver Disease Is Common Among Young People Living With HIV
“Around one third of young people living with HIV may have non-alcoholic fatty liver disease (NAFLD), according to study findings published in AIDS. The analysis found that fatty liver disease was only partially explained by overweight and metabolic syndrome.”

Hepatitis C a growing threat to moms, babies. But screening is inadequate.
“During her third pregnancy, Jamie Smith was itchy. Crazy itchy. Her obstetrician diagnosed her with cholestasis of pregnancy, a serious complication associated with liver disease. Her baby was at risk for being premature or even stillborn, so she was induced at 38 weeks.”

Hepatitis C treatment and cure targets for people living with HIV still not being met in Europe
“While over 90% of people living with HIV in Europe have been tested for hepatitis C, diagnosis remains suboptimal in the east of the continent. In three of five European regions, fewer than 80% of people with HIV and hepatitis C co-infection have received hepatitis treatment and the proportion who have been cured does not exceed 80% in any region. The study published in the March issue of AIDS also shows that there are significant differences between countries.”

Hepatitis E virus defies alcohol-based hand disinfectants
“The hepatitis E virus (HEV) can cause serious liver inflammation and is the most common cause of acute virus-mediated hepatitis worldwide. Infection can be prevented through appropriate hygiene measures. Scientists have investigated the effectiveness of various common hand disinfectants against HEV. They were able to show that most formulations do not completely inactivate the virus.”

Pamela Anderson was given ’10 years’ to live during her years-long health battle – signs
“Pamela Anderson became a household name after regularly appearing in Playboy magazine and landing a major acting role in Baywatch in the 90s. That decade, which was an eventful time for the star, is the subject of a new series on Disney+ called Pam & Tommy. Pamela’s life has attracted much fanfare but what is less publicised is her battle with hepatitis C, which dragged on for more than 15 years.”

Pandemic Era Tests May Speed Hepatitis-C Detection
“The pandemic has exacerbated the challenge. Three-quarters of surveyed state viral hepatitis programs reported losing staff and cutting preventive services. Laboratory and prescription drug data show a sharp decline in hepatitis C diagnosis and treatment in 2020.”

Study Assesses Real-world Outcomes of Immunotherapy in Patients With HCC, Comorbidities
“A poster presentation from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium suggests more research is needed to confirm the optimal treatment algorithms for patients with hepatocellular carcinoma.”

Antihistamines May Reduce Risk of Hepatocellular Carcinoma in Patients With Viral Hepatitis
“A new study showed a reduced risk of hepatocellular carcinoma (HCC) in patients with viral hepatitis who used H1-antihistamines (AHs), compared with those who did not. The results were published in the Journal of Clinical Oncology.”